Opinion: AbbVie-Landos Deal Signals Continued Momentum for Next-Gen I&I Drugs
This transaction is the latest to highlight Big Pharma’s growing interest in developing novel targets for inflammation and immunology (I&I) treatments, as well as the potential for cutting-edge computational drug development.